The patients of cystic fibrosis (CF), their families, and public health experts are pinning their hopes on the expected outcome from the Karnataka High Court regarding availability of affordable ...
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...
BofA raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $567 from $555 and keeps a Buy rating on the shares. After having ...
Vertex Pharmaceuticals (NasdaqGS:VRTX) Advances Diabetes Portfolio Despite 2% Decline in Share Price
Vertex Pharmaceuticals saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The company ...
Jim Lebenthal names Vertex Pharmaceuticals as his final trade. Joshua Brown says Netflix is close to its 52-week high. Markets are swinging wildly, but for Matt Maley, it's just another ...
Vertex Pharmaceuticals (Nasdaq: VRTX) specialises in treatments for rare diseases. It has eight approved medicines on the market. Seven of these are medicines for various types of cystic fibrosis ...
Vertex Pharmaceuticals (NASDAQ:VRTX) ended a four-day winning streak on Thursday after UnitedHealth (NYSE:UNH) placed its new pain medication Journavx in a less favorable Tier 3 coverage in two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback